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Gestational pemphigoid (pemphigoid gestationis, PG) is a rare autoimmune skin disorder occurring characteristically
during pregnancy. Autoantibodies against placental BP180 (also known as BPAG2 or collagen XVII) cause damage to
the skin basement membrane, resulting in severe itching and blistering rash over the body and the extremities. The
diagnosis of PG is confirmed by immunofluorescence analysis of a skin biopsy, while serum levels of pemphigoid
antigen BP180 antibody can be used to assess disease activity. PG with mild symptoms can be treated with topical
corticosteroids, while oral corticosteroids are the mainstay in treatment of severe PG. PG usually flares up at the
time of delivery, and resolves spontaneously shortly after. However, relapses in subsequent pregnancies are
common. As PG has been linked to the risk of prematurity and fetal growth restriction, prenatal monitoring jointly
by a dermatologist and an obstetrician is recommended. Mothers should also be informed of the potential risk of
re-activation of the disease in subsequent pregnancies and during hormonal contraception.Introduction
Gestational pemphigoid (pemphigoid gestationis, PG) is
a rare autoimmune skin disorder that occurs during preg-
nancy. PG belongs to the pemphigoid group of auto-
immune skin diseases that cause blistering of the skin and
mucosal membranes [1]. The most common form is bul-
lous pemphigoid (BP); other major forms include mucous
membrane pemphigoid and linear IgA disease. In pem-
phigoid diseases, autoantibodies target hemidesmosomal
proteins that maintain adhesion between basal kerati-
nocytes and the basement membrane, thereby breaking
cell-matrix adhesion and typically causing subepidermal
blisters. These proteins include bullous pemphigoid antigen
180 (BP180, i.e., BPAG1 or collagen XVII) and BP230
(i.e., BPAG1-e). The IgG autoantibodies to BP180 are
pathogenic but the role of autoantibodies against BP230 in
blister formation is unclear [1].
PG was previously called herpes gestationis, but this
misnomer should be withdrawn, since there is no true
connection to herpetic diseases [2]. Studies looking for
the epidemiology of PG are rare. Population-based stud-
ies have reported an annual incidence ranging between
0.5 and 2.0 cases per 1 million people in France, Kuwait
and Germany [3-5]. In a retrospective study, PG was
found in 4.2% of 505 pregnant patients evaluated in* Correspondence: laura.huilaja@oulu.fi
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unless otherwise stated.university-based dermatologic pregnancy clinics [6]. Based
on the current epidemiological data PG is estimated to
occur in one out of about 40,000-50,000 pregnancies [7]
with no difference in racial distribution [8,9]. Single cases
have been described in association with molar pregnancies
[10] and trophoblastic tumors [11].
Clinical features
PG may appear at any time during pregnancy or puer-
perium, but the most common time of symptom onset is
during the second and third trimester. Intense abdom-
inal itching usually begins around the navel, with varied
red papules, urticarial plaques or annular target lesions
(erythema multiforme –like) appearing in the itchy
areas, followed by blistering after a few weeks (Figure 1).
Bullous lesions vary from small vesicles to large blisters
with a thick roof; however, some PG patients have no
blisters at all (Figure 1). Typically, the skin symptoms
first appear in the abdominal area, but according to an
American study (n = 10) it is also common for cutaneous
manifestations to appear first in the extremities [12]. In
a Finnish study (n = 12) the symptoms started in the ab-
dominal area in all patients, and 92% developed blisters
as the disease progressed [13]. Facial and mucosal lesions
are uncommon [12,14], but in some reports severe mucosal
lesions were associated with more persistent disease [15].
The symptoms of PG usually alleviate a few weeks be-
fore delivery, but the disease is re-activated in 75% of the
patients at the time of delivery. The remitting, relapsingLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Skin findings of gestational pemphigoid (PG). Urticarial papules and plaques usually appearing first on abdominal area (A). Minor
umbilical lesions of PG (B). Vesicles (C) and bullae (D) following urticarial plaques. PG lesions on extremities (E-G).
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with progestin, which has immunosuppressive properties,
and with changes in progestin levels: an increase in late
pregnancy followed by a sharp fall during delivery [7,16].
According to a large PG study (n = 87), the average dur-
ation of symptoms is 16 weeks and the majority of mothers
are symptom-free 6 months after the delivery, the duration
of postnatal manifestations varying between 2 weeks and
12 years [16].
Etiopathology
The pathogenesis of PG remains unknown. The pres-
ence of MHC II-class HLA-antigens DR3 and DR4 or
their combination has been shown to be clearly more
common in women with PG compared to normal popu-
lation [17]. Placental and fetal tissues contain paternal
tissue antigens that are foreign to the maternal immune
system. However, the maternal immune system does not
normally react against these foreign antigens. In patients
with PG, MHC II-class molecules that are normally not
present in the placenta have been detected in tropho-
blastic placental cells and amniochorionic stroma cells.
As a result of partial breakdown of the syncytiotropho-
blast cell layer of placental anchor villi, MHC II mole-
cules are thought to get in contact with the maternal
immune system, causing a (semi) allogeneic immune reac-
tion against the BP180 molecule [18-20].
BP180 (also known as BPAG1 or collagen XVII) is a key
structural protein of hemidesmosomes linking the epider-
mis and dermis. It consists of a short intracellular domain
and a large extracellular domain [21]. Besides the skin
basement membrane zone, BP180 is found in the placen-
tal tissue and fetal membranes. Placental BP180 is detect-
able in cytotrophoblastic cells as early as from the firsttrimester [22]. In PG, antibodies are mainly directed
against the same BP180 epitopes as in bullous pemphig-
oid [23,24]: most commonly against the epitopes found
in NC16A, the largest non-collagenous domain of BP180,
but antibodies against intracellular BP180 domains and
other extracellular domains of BP180 have also been ob-
served [25]. In addition, antibodies against another struc-
tural basement membrane protein, BP230, have been
detected in about 10% of patients with PG, but this is con-
sidered to be secondary and clinically insignificant [7,26].
The cross-reaction between placental antibodies and skin
BP180 causes the typical skin symptoms of PG [7,27].
To the best of our knowledge, PG-related animal models
do not exist. In BP, the pathogenicity of autoantibodies
directed against the NC16A domain has been confirmed
in several mouse models [1,28]. Severe blistering and
high mortality prevents the use of experimental BP-mice
for breeding to imitate a PG-like condition. The transfer
of autoantibodies from mother with PG to newborn is to
some extent simulated in a gene-targeted mice model in
which the maternal transfer of NC16A antibodies results
in blistering in the neonatal BP180-humanized mice [29].
Diagnosis
The diagnosis of PG is preferably made by a dermatologist,
but all physicians treating pregnant women, i.e., general
practitioners and obstetricians, should be able to consider
PG. A biopsy for histopathology is not needed; the diagno-
sis is based on clinical picture, direct immunofluorescence
microscopy and serology [1,30,31]. Direct immunofluores-
cence examination of a snap-frozen perilesional skin bi-
opsy reveals the linear accumulation of complement C3 in
the basement membrane zone at the interface of the epi-
dermis and dermis (Figure 2). Linear IgG positivity is also
Figure 2 Linear complement 3 (C3) (arrow) fluorescence in immunofluorescence analysis of perilesional skin biopsy is diagnostic for
gestational pemphigoid. Primary magnification 200 × .
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criterion for the diagnosis [27,32]. If PG is suspected,
measurement of serum BP180 antibody level is recom-
mended, as it correlates with the degree of disease severity
and facilitates assessment of treatment response [33,34].
Since the BP180 NC16A ELISA is sensitive and specific to
PG, it has even been proposed as a PG screening test or to
be sufficient for the PG diagnosis in conjunction with typ-
ical clinical symptoms [33-35]. Serum autoantibodies can
also be detected with traditional indirect immunofluores-
cence microscopy or the complement binding test on salt-
split skin [1,30,31].Differential diagnosis
Since PG is an extremely rare condition, other dermato-
logic reasons for itchy cutaneous eruptions (Table 1) oc-
curring during pregnancy should be ruled out. Pregnancy
may influence the clinical picture of common skin dis-
eases that either precede pregnancy or coincide with it by
chance. Especially PG with atypical symptoms such as
non-intense pruritus, mild erythematous papules and pla-
ques or eczematous lesions represents a true challenge for
clinical diagnostics.
The most important differential diagnosis alternatives for
PG are the other specific dermatoses of pregnancy which
Table 1 Differential diagnostics of pregnancy associated pruritic dermatoses





Estimated incidence Most common pregnancy
associated dermatose. 1:5–1:20
1:160 1:50–1:5000 1:40000–1:50000
High-risk groups Primigravidity Multiparity
Obesity
Multiple pregnancy
Skin manifestations Pruritus Pruritus (Nocturnal) pruritus Pruritus

















Extensors of the extremities Striae
Thighs
Body
Studies S-IgE levels may be elevated Negative DIF Elevated total serum bile
acid levels




I-II III III II-III




No fetal risks No fetal risks Stillbirth Prematurity
Fetal growth restriction
Newborn No harm to newborn No harm to newborn No harm to newborn Possibility for transient skin
blistering





Activation of symptoms is possible
during menstruation and hormonal
contraceptive use
S-IgE: serum immunoglobulin E; DIF: direct immunofluorescence microscopy; BP180-ELISA: bullous pemphigoid 180 ELISA.
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eruption of pregnancy (PEP) and intrahepatic cholestasis of
pregnancy (ICP) [6,36-40]. AEP is the most common
pregnancy-specific skin disease, which typically appears in
the first and second trimesters [40]. About 20% of the pa-
tients with AEP have a pre-existing atopic dermatitis with
a typical clinical picture, whereas the remaining 80%
present widespread eczematous changes or papular lesions
and have no previous history of atopic eczema or have
been symptomless since childhood [31]. The greatest dif-
ferential diagnostic challenge of PG is PEP, previously
known as Pruritic Urticarial Papules and Plaques of Preg-
nancy (PUPPP), with intensely pruritic urticarial papules
and plaques during the last trimester. Despite rather simi-
lar clinical features, negative immunofluorescence analysis
of perilesional skin biopsy in PEP differentiates it explicitlyfrom PG [38,39]. Similar to PG, PEP symptoms usually
start on the abdomen, but PEP lesions typically spare the
umbilical region. ICP, which is associated with significant
fetal risks, can present in the last trimester with pruritus,
and thus it should be considered in differential diagnosis of
PG [40]. Patients with ICP do not have primary skin le-
sions, but due to severe pruritus and scratching may
develop secondary excoriations or even prurigo nodularis-
like changes, usually on the extremities [31].
Management
Due to the rarity of PG no randomized studies have
been published and treatment recommendations are
based on clinical experience and studies from treatment
of other skin diseases. PG symptoms can be quite debili-
tating, but the condition does not constitute a direct
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the benefit of the medication to the mother is critically
weighed up against possible risks to the fetus. The aim
of the treatment is to suppress the excessive itching and
to prevent formation of new blisters [41].
According to current recommendations PG patients
with mild symptoms (about 19% of the patients) should
be treated with potent or very potent topical corticoste-
roids (for example betamethasone valerate or clobetasol
propionate) [1,30]. Controlled studies with BP patients
have shown that topical treatment with highly potent
corticosteroid is as effective and safe as oral prednisolone
0.5 mg/kg/day [42]. During pregnancy, mild or moderate
topical corticosteroids are preferred to potent or very
potent ones because of the risk of fetal growth restric-
tion associated with the latter [43]. When necessary, po-
tent or very potent topical corticosteroids can be used
for the therapy of PG for as short duration as possible,
since their potential for fetotoxicity is less than that of
systemic corticosteroids [43-45].
The combination of oral antihistamines with topical cor-
ticosteroids, most commonly cetirizine, is usually employed
to relieve the itching, despite the fact that clinical efficacy
studies in PG are lacking [1,16,27,30]. In general, second-
generation H1-antihistamines are currently preferred to
first-generation antihistamines based on the potential ser-
ious anticholinergic and central nervous system side ef-
fects of old sedating antihistamines and the longer-lasting
antipruritic effects of the modern antihistamines [46].
First-generation antihistamines have no definitive increased
teratogenic risk, and the second-generation antihistamines
cetirizine, levocetirizine and loratadine are also recom-
mended for use in pregnancy [44,46].
Corticosteroid treatment has become the standard of
care for first-line systemic therapy of severe PG thanks
to its treatment response and tolerable safety profile.
Most of prednisolone is inactivated by placental de-
hydrogenase enzyme (11-hydroxysteroid dehydrogenase-
2) before reaching the fetal circulation. As fluorinated
corticosteroids (betamethasone and dexamethasone) are
not metabolized by placental dehydrogenase enzyme,
prednisolone is considered the primary treatment alterna-
tive. [1,30,47]. The initial dose of prednisolone is usually
0.25-0.5 mg/kg/day, and the response is usually good. If
formation of blisters does not decrease within a few days,
the dose is increased until no new blisters appear. The
cortisone dose is gradually decreased about 1–2 weeks
after the symptoms have been brought under control, and
discontinued altogether if possible.
The side effects of long-term systemic corticosteroid
treatment are well-known. Previous studies have dem-
onstrated that in the treatment of BP the use of oral
prednisolone is associated with more frequent severe ad-
verse events and increased mortality compared to topicalcorticosteroids [1,30,42]. However, BP patients are much
older and have more severe comorbidities than PG pa-
tients. In addition, the duration of prednisolone treatment
is shorter and the dosage is smaller in PG than in BP,
which further decreases the risk of side effects. During
pregnancy, the use of prednisolone in the first trimester
causes an increased risk of malformations, especially orofa-
cial clefts [44]. In the last trimester prednisolone may result
in intrauterine growth retardation, gestational diabetes,
eclampsia and premature delivery [44].
Plasmapheresis [48], immunoadsorption [49,50] and
intravenous immunoglobulin G-infusion [51-54], which are
not contraindicated during pregnancy, have in some cases
been used to treat PG even prior to the delivery. Removal
of antibodies with immunoadsorption gives quick symptom
relief especially in PG cases with severe postnatal symp-
toms, as there is no placenta to maintain an autoimmune
reaction [50]. Prenatal treatment with cyclosporine com-
bined to prednisolone has been reported in two cases with
good treatment response [13,55], and in one case cyclo-
sporine was used after intravenous immunoglobulin in
persistent postnatal PG [56]. Case reports on the use of
tetracycline, cyclophosphamide, azathioprine, dapsone
and rituximab to treat PG with persisting postnatal symp-
toms have been published, but these agents are avoided
prenatally due to potential short- and long-term fetal
effects. [7,41].
PG lesions usually disappear 12–16 weeks after the de-
livery, with no scarring, and postnatal oral cortisone treat-
ment can normally be discontinued fairly soon. However,
sometimes treatment has to be resumed as the disease
flares up again [16,27]. When systemic cortisone is given
at the average doses used in the treatment of PG, it does
not prevent breastfeeding, and breastfeeding has been
shown to reduce the symptoms of PG [17,7,12].
Fetus and the newborn
The risk of preterm birth and fetal growth restriction is
greater in PG pregnancies compared to normal popula-
tion [57-60]. The pregnancy risks of PG are thought to
be associated with mild placental failure caused by BP180
antibodies [13,27,60]. In addition to accumulation of C3
complement and IgG, mild villitis and collections of im-
mature fibrotic villi have been observed in histologic ex-
aminations of PG placentas [22]. Antibody concentrations
do not as such correlate with the occurrence of pregnancy
complications, and no association has been demonstrated
between cortisone treatment and PG pregnancy complica-
tions [60]. No follow-up guidelines for pregnancies com-
plicated by PG have been published, most likely due to the
rarity of the condition.
In the largest data set on PG pregnancies (n = 87) pub-
lished in 1999 the rate of miscarriages was comparable
to the risk in normal population (15%), with the majority
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ever, in a more recent British-Taiwanese study with 70 pa-
tients late miscarriages and fetal deaths were observed in
as many as 6% of the patients [60].
About 16-34% of PG patients are estimated to give
birth prematurely [13,58-60]. Premature delivery is more
likely if PG begins in the 1st or 2nd trimester or if the
skin symptoms include blistering [60]. In a Finnish PG
study, 25% of the deliveries were premature (the corre-
sponding rate in the Finnish population during time of
study was around 5%) [13,61]. The proportion of prema-
ture deliveries among pregnant women with PG was
similar to that in previously published studies, even though
all patients, with one exception, had blistering PG. All pre-
mature births occurred after the 35th gestational week,
and PG had no effect on neonatal mortality [13]. Vaginal
ultrasound is considered the gold standard in charting cer-
vical dilation in women at risk of preterm delivery [62].
Although preterm delivery is difficult to predict, we rec-
ommend obstetric follow-up with vaginal ultrasound due
to the increased risk of preterm delivery.
In the British-Taiwanese study with 70 patients, fetal
growth restriction was observed in 34% [60], the likeli-
hood of its occurrence correlating with early onset of
PG. In a Finnish study, only one mother developed pre-
eclampsia combined with fetal growth restriction, which
is in line with the general prevalence in Finnish popula-
tion. However, 50% of the patients in our study had an
abnormal placental weight/birth weight ratio [13]. The
blood flow profile of the umbilical artery is used in clin-
ical practice to diagnose placental failure [63]. In a PG
case report where pregnancy was complicated by pre-
eclampsia and fetal growth restriction, abnormal end-
diastolic blood flow was reported in the umbilical artery
[64]. Among 12 Finnish PG patients increased umbilical
artery pulsatility was detected only in one pregnancy
with pre-eclampsia and fetal growth restriction; all other
PG pregnancies showed normal umbilical artery blood
flow findings and biophysical scores [13], suggesting that
clinically significant placental failure is rare in PG.
There is only little information available on the effect
of PG on the newborn infant. No congenital abnormal-
ities have been linked to PG [58,60]. According to the
data from 12 Finnish PG patients, birth weight, umbilical
artery pH, Apgar scores and neonatal morbidity did not
differ from normal population [13]. The IgG antibodies
of PG pass through the placenta, but PG blisters develop
in only about 3% of newborn infants [14,16,57]. Skin
symptoms in newborns usually resolve quickly without
treatment as antibody levels decrease. According to a
Japanese case report, antibody levels in newborn infants
are comparable to those in mothers; the levels in both
are reduced by half in about 15 days. Since the clinical
status of the newborn often improves rapidly, it seemsthat other factors besides autoantibodies contribute to
the formation of blisters in newborns [65]. If PG in the
mother was treated with large doses of cortisone, the
pediatrician should be informed of the possibility of neo-
natal adrenal insufficiency. There are no data on the long-
term prognosis of children of PG mothers.
Prognosis
Recurrence of PG in subsequent pregnancies is likely,
and symptoms are usually more severe, with earlier on-
set. In patients with an earlier PG episode the likelihood
of pregnancy with no symptoms is estimated to be 5-8%,
but the reason for the lack of symptoms is unknown.
[16,17]. In a Finnish study, PG recurred in two cases,
while 67% of the subsequent pregnancies were symptom-
free (n = 4/6). The large proportion of symptom-free preg-
nancies is most likely due to the small number of patients,
but ethnic factors may also play a role [13]. Perfect HLA-
DR match between the mother and the fetus may explain
some of the cases, but pregnancy may be free from PG
symptoms even in the absence of identical HLA-DR
type [16,17] and even if the symptoms of PG have been
persistent [66].
At the postpartum examination, mothers with PG
should be reminded of the possibility of relapse during
menstruation and/or in connection with hormonal contra-
ceptive use. Susceptibility for recurrence may persist for
years [16,37]. In a large British study, about 11% of the pa-
tients experienced a relapse during oral contraceptive use,
but in smaller studies the incidence has been as high as
50% [14,16,17]. The low relapse rate in the British study
was thought to be associated with the infrequent use of
oral contraceptives after PG pregnancy [16]. Women who
have had PG have also been described to be more suscep-
tible to other autoimmune diseases; the prevalence of
Graves’ disease increases in particular, from 0.4% in nor-
mal population to as high as 10.6% [16]. Proneness to
Hashimoto’s thyroiditis, autoimmune thrombocytopenia
and pernicious anemia has also been reported to be in-
creased [16,67].
Conclusion
Gestational pemphigoid is a rare skin disorder in preg-
nancy. The severe itching and blistering caused by the
disease can be quite debilitating. The diagnosis of PG is
made in a specialized care setting at a dermatology de-
partment. Since PG is associated with a risk of prema-
turity and fetal growth restriction, pregnancy monitoring
by an obstetrician is recommended. Mothers with PG
should be informed of the natural course of the disease,
good fetal prognosis, the possibility of relapses after de-
livery, and the risk of relapses in subsequent pregnancies
and with hormonal contraception.
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